J&J’s MS drug ponesimod receives approval in the US

Now that Ponvory has received regulatory approval, it will enter an increasingly crowded market, with rivals including Novartis’ SLP receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod). ... There is also

Cortellis Drugs to Watch in 2020 report

To succeed, it will have to differentiate from its direct competitors, particularly the first-in-class S1P1 agonist Gilenya, by leveraging potential cardiovascular safety advantages.

J&J aims for US approval of MS drug ponesimod

If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only ... There is also the

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

S1P receptor modulator franchise based on Gilenya(fingolimod) and recently-launched follow-up  Mayzent(siponimod), which for now is approved for secondary progressive forms of MS only. ... There is also a looming threat of generic competition to Gilenya

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]